Medtronic plc

NYSE:MDT

Medical - Devices

Healthcare
$100.72 +0.96%

+$0.75 today

Market cap
$128.84B
Beta
0.60
P/E (TTM)
21.1
EPS (TTM)
$3.74
Dividend yield
3.60%
52W Low $73.31High $106.33

Volume 6.47M

Average 11.36M

MDT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Medtronic plcNYSE: MDT

Research & Development · Q1 FY2027 · quarter ended Jul 2026

Research & development grows in line with its trailing trend

Q1 FY2027 research & development of $771M rose 6.2% year over year, ahead of the +4.9% change in trailing-twelve-month research & development. Sequentially, it rose 14.9% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.

Context

  • Research & development amounted to 7.9% of revenue in FY2026, down 0.2 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +6.2% holds above the trailing-twelve-month pace of +4.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJul 2026
$771M+14.9% QoQ
Last fiscal yearApr 2026
$2.87B+5.2% YoY
LTMJul 2026
$2.92B+4.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.2%——
1 year+5.2%——
3-year CAGR+2.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2026
2.87B USD
Year-over-year change
+5.2%
4-year CAGR
+1.1%

Research & Development vs competitors

How MDT compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.9% is the 5th highest of 9, against a peer median of +6.7%.
  • Research & development amounts to 7.8% of revenue for MDT, versus a peer median of 10.0%.
MDT Competitors
Research & Development for MDT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$2.92B USD+4.9%+2.1%7.8%
BSXBoston Scientific CorporationLTM Jun 2026$2.15B USD+17.3%+15.8%10.3%
PHGKoninklijke Philips N.V.LTM Jun 2026€1.72B EUR-2.6%-6.7%9.7%
SYKStryker CorporationLTM Jun 2026$1.66B USD+10.1%+8.8%6.4%
EWEdwards Lifesciences CorporationLTM Jun 2026$1.09B USD+3.3%+4.5%16.7%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$442.9M USD-0.2%+4.1%5.2%
LIVNLivaNova PLCLTM Sep 2026$202.57M USD+14.5%+6.0%13.4%
PENPenumbra, Inc.LTM Jun 2026$92.25M USD+1.9%+4.2%6.1%
AVRAnteris Technologies Global Corp.LTM Mar 2026$70.12M USD+24.4%+57.8%3788.3%
Peer median (excluding MDT) —+6.7%+5.3%10.0%

Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Apr 2026
Revenue31.69B31.23B32.36B33.54B36.36B
Cost of Revenue10.15B10.72B11.22B11.63B12.72B
Gross Profit21.54B20.51B21.15B21.91B23.64B
Gross Margin68.0%65.7%65.3%65.3%65.0%
Research & Development2.75B2.7B2.74B2.73B2.87B
Selling, General & Admin10.29B10.42B10.74B10.85B11.78B
Operating Expenses15.79B15.02B16B15.95B17.18B
Depreciation & Amortization2.71B2.7B2.65B2.86B2.96B
EBITDA8.78B8.7B8.2B9.22B9.81B
EBITDA Margin27.7%27.9%25.3%27.5%27.0%
Operating Income5.75B5.49B5.14B5.96B6.47B
Operating Margin18.2%17.6%15.9%17.8%17.8%
Interest Income00000
Interest Expense553M636M719M729M715M
Other Income / Expenses(235M)(121M)(307M)(327M)(331M)
Income Before Tax5.52B5.36B4.84B5.63B6.14B
Pre-Tax Margin17.4%17.2%14.9%16.8%16.9%
Income Tax Expense456M1.58B1.13B936M1.3B
Net Income5.04B3.76B3.68B4.66B4.8B
Net Margin15.9%12.0%11.4%13.9%13.2%
EPS (Basic)3.752.832.773.633.75
EPS (Diluted)3.732.822.763.613.73
Weighted Avg Shares1.34B1.33B1.33B1.29B1.28B
Weighted Avg Shares (Diluted)1.35B1.33B1.33B1.29B1.29B

Medtronic plc

NYSE:MDT

Intrinsic Alpha fair value

Locked

Current Price

$100.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.